Medical Oncology Service: About Us
The Medical Oncology Service is part of the Office of the Clinical Director, Center for Cancer Research (CCR) at the National Cancer Institute (NCI).
Medical oncology staff and fellows support patients who are participating in NCI-CCR clinical protocols at the National Institutes of Health (NIH) Clinical Center, located on the NIH campus in Bethesda, Maryland. The NIH Clinical Center is the nation’s largest hospital totally dedicated to clinical research.
- Develop novel therapeutic research strategies for treating cancer and test these strategies by conducting clinical research across a spectrum of diseases and mechanisms;
- Provide outstanding clinical care to adult cancer patients enrolled in NCI-CCR research protocols, including in-patient and out-patient care services;
- Train physician-scientists through the NIH Hematology Oncology Fellowship and the Immunotherapy Fellowship in a laboratory-to-clinic translational research setting to develop their expertise in medical oncology research and to support their board certification by the American Board of Internal Medicine.
Other Training Programs
Additional training opportunities in medical oncology at NIH are highlighted below.
Senior Medical Students – To learn more about 4-week clinical rotations in medical oncology at the NIH Clinical Center, visit the Clinical Electives Program.
Residents – Elective rotations offer residents the opportunity to have direct experience in the care of patients enrolled in investigational protocols at the NIH Clinical Center. For more information, visit Elective Rotations for Residents and Clinical Fellows.
Clinical Trials at the NIH Clinical Center
The clinical trials conducted by the NCI-CCR on the National Institutes of Health (NIH) campus in Bethesda, Maryland represent the core of our clinical program. At the CCR, basic and clinical science are seamlessly integrated with a mission to reduce the burden of cancer through exploring, discovering, and the translating new approaches into compassionate and effective care for all cancer patients. CCR clinical studies are aimed at:
- Answering critical questions about a particular disease or disease process
- Identifying promising new therapeutic interventions that can then be confirmed in larger studies carried out across the country at participating NCI-supported cancer centers.
Genitourinary Malignancies Branch
James L. Gulley, M.D., Ph.D.
Andrea B. Apolo, M.D.
William L. Dahut, M.D.
Marijo Bilusic, M.D., Ph.D.
Kazusa Ishii, M.D.
Ravi A. Madan, M.D.
Fatima Karzai, M.D.
Philip Arlen, M.D.
Howard Parnes, M.D. (DCP)
Yang-Ming Ning, M.D. (FDA)
Hussein Abdul Sater, M.D.
Jason Redman, M.D.
Charalampos Floudas, M.D., DMSc, MS
Scot Niglio, M.D., M.S.
Developmental Therapeutics Branch
James Doroshow, M.D.
Alice Pinting Chen, M.D.
Jaydira Del Rivero, M.D.
Geraldine H. O'Sullivan Coyne, M.D.
Richard Piekarz, M.D., Ph.D (CTEP)
Sheila Prindiville, M.D., M.P.H. (CCCT)
Elad Sharon, M.D., M.P.H. (CTEP)
Howard Streicher, M.D. (CTEP)
Naoko Takebe, M.D., Ph.D. (DTC)
Anish Thomas, MBBS, M.D.
Nitin Roper, M.D.,M.Sc.
Hoyoung Maeng, M.D.
Thoracic and GI Malignancies Branch
Raffit Hassan, M.D.
Tim F. Greten, M.D.
Arun Rajan, M.D.
Eva Szabo, M.D. (DCP)
Shakun Malik, M.D. (CTEP)
Azam Ghafoor, M.D.
Cecilia Monge, M.D.
Chen Zhao, M.D.
Chanqing Xie, M.D., Ph.D.
Lymphoid Malignancies Branch
Thomas A. Waldmann, M.D.
Wyndham Wilson, M.D., Ph.D.
Kevin C. Conlon, M.D.
Christopher Melani, M.D.
Milos Miljkovic, M.D., MSc.
Mark J. Roschewski, M.D.
Dickran Kazandjian, M.D. (FDA)
Mark R. Gilbert, M.D.
Laboratory of Tumor Immunology and Biology
Julius Strauss, M.D.
NCI Immunotherapy Fellowship
This training program is designed for physicians who have completed a medical oncology fellowship program in the United States and who seek specialized training in immunotherapy with clinical trials and clinical trial development.
There are multiple opportunities for training in clinical immunotherapy at the Center for Cancer Research (CCR), National Cancer Institute (NCI), with active clinical programs in therapeutic cancer vaccines, immune checkpoint modulation, adoptive cellular therapies (both TCR transgenic and CAR-T therapy) and antibody-based immunotherapies. This training program, at the CCR in Bethesda, Maryland, allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. This 1-year fellowship provides opportunities to understand how to design, write and run clinical trials, how to treat patients, how manage toxicities, as well as opportunities to work with multiple experimental agents.
Funding and Co-sponsorship
This fellowship is co-sponsored by the National Cancer Institute and the Society for Immunotherapy of Cancer (SITC) and made possible, in part, by an educational grant from EMD-Serono.
How to Apply
To apply, please send your CV, statement of purpose, three personal references, and your documentation of board eligibility status or certification status to firstname.lastname@example.org
Application Period Opens: August 3, 2020 - September 14, 2020
Review Period: October 2020
Notification Date: November 10 - November 15, 2020
- Work with internationally recognized experts in immunotherapy
- Learn management of immune-related adverse events
- Develop experience in writing and running immunotherapy clinical trials
- Develop experience with a wide array of immunotherapy approaches
- Immunue checkpoint inhibitors
- Adoptive cellular therapy (CAR-T or TCR transgenic approaches)
- Therapeutic vaccines
- Combination immunotherapy approaches
- Possibilities for attending and presenting at national/international meetings
- Attend and participate in regularly scheduled NIH immunotherapy conferences
- Make a difference in the lives of patients with cancer at the largest hospital in the world devoted solely to research
- Salary is based on applicable laws, regulations, and policies
Immunotherapy for cancer has fundamentally changed the way we are treating patients with metastatic disease. The exploding interest in immunotherapy has been propelled by the rapid and durable responses seen in treated patients, often with little to no side effects. Billions of dollars are now being poured into immunotherapy research with multiple new approvals since 2010 and even more expected in the near future. However, the basics of immunotherapy taught in medical schools when our current generation of medical oncologists trained are woefully inadequate for the high-tech immunotherapies being tested with ever-increasing intensity. In addition, the side effect profile with immunotherapies is related to the mechanism of action and is unique among anti-cancer agents. The mechanism of action is more complex as often agents don’t directly target the cancer but rather target the immune system which, in turn, targets the cancer. Furthermore, the kinetics of a clinical response following immunotherapy may be different from conventional therapy which is important for practitioners and patients alike to know to help manage expectations. Finally, the mechanisms of resistance to immunotherapy are also unique and a better understanding of these mechanisms will guide combination therapy.